Fresh Use Of Targeted Therapy Advances Treatment Of Early HER2-Positive Breast Cancer

JACKSONVILLE, Fla. -- The news that the world’s first targeted therapy, trastuzumab (Herceptin), is now available for many women with early-stage HER2-positive breast cancer “highlights a truly significant advance in the management of breast cancer,” says Edith Perez, M.D., director of Mayo Clinic’s Breast Clinic in Jacksonville, Fla.>>> Discuss This Story